Correlation of Plethysmograph Variability Index with Inferior Vena Cava Index in Spontaneously Breathing Neonates - A Cross Sectional Study.

Inferior vena cava (IVC) indices are commonly used to assess the need for fluid bolus during shock. It needs expertise and is difficult to do during surgical procedures. Plethysmograph variability index (PVI) is a simpler non-invasive tool used to measure fluid responsiveness in adults. However, the data on PVI in neonates is limited. This cross-sectional observational study was done at a tertiary level NICU to correlate PVI and IVC among spontaneously breathing neonates. The PVI was documented using the Masimo Radical 7 pulse oximeter. The IVC collapsibility index (IVC CI) was determined by bedside ultrasound. The Spearman correlation coefficient was analyzed. The PVI showed strong positive correlation with IVC CI (rho = 0.64, 95% CI: 0.474-0.762) (p <0.001). Thus, PVI can be a useful tool for hemodynamic monitoring of neonates. However, further studies are needed before applying it to clinical use.

Plethysmograph Variability Index Values in Healthy Neonates - An Observational Pilot Study.

OBJECTIVES: To establish normative data of plethysmograph variability index (PVI), a simple non-invasive tool to measure fluid responsiveness, in neonates. METHODS: All healthy term and late preterm neonates were enrolled. PVI was recorded by pulse-oximeter on first three days of life along with other vital parameters. Data was analysed using SPSS software. RESULTS: The median PVI value was noted to be 21 with a wide range. The distribution of PVI did not differ according to day of life/ gestational age/ gender/ weight for gestational age. It did not significantly correlate with heart rate, gestational age or birth weight. A weak positive correlation was noted between PVI and PI (Rho = 0.157, p <0.001). CONCLUSIONS: PVI normative data in neonates has been presented. Serial trend of PVI values is more useful than a single value in making clinical decisions.

Corticotrophin-ACTH in Comparison to Prednisolone in West Syndrome - A Randomized Study.

OBJECTIVE: To compare the outcomes of adrenocorticotrophic hormone (ACTH) and Prednisolone therapy in children with West syndrome. METHODS: The study was done at a tertiary health centre for children. The pediatric neurologist at the centre enrolled children into the study based on the inclusion and exclusion criteria. They were evaluated in detail, classified according to etiologic type and then, randomly assigned into two treatment groups, either ACTH or Prednisolone. They were followed at regular intervals till 6 mo. RESULTS: There was no difference between ACTH and Prednisolone groups with respect to all the outcomes measured. Cessation of spasms was achieved in 6/15 (40%) in Prednisolone group and 9/18 (50%) in ACTH group (p = 0.3906). The average time for achieving cessation was 6.9 and 8 d in ACTH and Prednisolone groups respectively (p = 0.7902). The relapse rates were 18.18 and 50% in ACTH and Prednisolone groups respectively (p = 0.28). The side-effects profile, subsequent epilepsy rates and improvement in milestones were similar in both the treatment groups. CONCLUSIONS: There is no significant difference in children treated with ACTH and Prednisolone. Study results cannot be generalized due to small sample size. However, Prednisolone can be a suitable alternative to ACTH in resource poor settings.